Chief commercial officer of NovoCure Limited (NASDAQ:NVCR) offload 11,175 shares
NovoCure Limited stock is being impacted by recent insider selling, in which in last week the chief commercial officer of the company Shah Pritesh offload NVCR shares. On June 27, 2019 he disposed of 11,175 shares of NovoCure Limited (NASDAQ:NVCR) of worth $65,037 as per SEC form 4.
The stock Earnings per share (EPS) and the diluted EPS are the profitability measures used in the fundamental analysis of companies. The figure of EPS only takes into account a NovoCure Limited (NASDAQ:NVCR) common shares, whereas the very important diluted EPS take into account all the convertible securities such as convertible bonds/convertible preferred stock, which are changed into equity or common stock. Dilutive effects occur when the number of shares increases, for example, through a new issue. If a company issues more shares to shareholders and other investors, this increases the number of shares outstanding and decreases the company’s earnings per share. Ultimately, this can decrease the stock price. NovoCure Limited (NASDAQ:NVCR) Diluted EPS is -0.59, whereas the EPS Estimate for next year is 0.53. The Annual EPS Growth of past 5 years is 5.90% and NovoCure Limited (NASDAQ:NVCR) yearly performance is 102.34% and net profit margin is -20.40%.
Key Performance indicators for NovoCure Limited (NASDAQ:NVCR), in last 4 months the performance of NVCR was 31.26% while its price to sale ratio is 21.64 and price to book ratio is 47.54. Company gross margin stands at 69.70% whereas its return on investment (ROI) is -19.60%.
On 28 June 2019, NovoCure Limited (NASDAQ:NVCR), a Healthcare sector firm, traded 3.28 Million shares in last trading session and stock advanced 3.91% with closing price of $63.23 per share. withNovoCure Limited (NASDAQ:NVCR) traded 3.28 Million shares. The NVCR distance from 20 day simple moving average is 11.37% and distance from 50-Day simple moving average is 22.87%.The relative strength index for stock is 69.53 and Average true range of NVCR is 2.42.
Analyst’s mean target price for NVCR is $57.83 while analysts mean recommendation is 2.00. The Stock value has moved between $26.02 – 61.99 in last one year. NVCR market capitalization is 5827.28 with beta of 2.40. Company has 2.10% insider ownership.
NovoCure Limited (NASDAQ:NVCR) is under coverage by number of analysts. Stock has got OUTPERFORM rating from 9 of Thomson Reuters analysts, 14 given HOLD rating to the stock and 1 given UNDERPERFORM rating. Buy rating has been given by 4 analysts to the company stock.